加齢黄斑変性に伴う地図状萎縮患者におけるダニコパンの研究

基本情報

NCT ID

NCT05019521

ステータス

中止

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

365

治験依頼者名

Alexion Pharmaceuticals, Inc.

概要

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

対象疾患

介入

依頼者（Sponsor）